SCHEMBL19902491

SCHEMBL19902491

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1cccc(OCCN2CCOCC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.47
HTR7 P34969 3/20 0.44
ROCK2 O75116 1/20 0.44
ROCK1 Q13464 1/20 0.44
EPHX2 P34913 1/20 0.44
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTR1A P08908 2/20 0.43
DRD2 P14416 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
ADRA1A P35348 1/20 0.43
HRH1 P35367 1/20 0.43
KCNH2 Q12809 1/20 0.43
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
POLB P06746 1/20 0.42
KDR P35968 1/20 0.42
MAPK14 Q16539 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452858 0.90 ROCK2 (0.48) PPARGHTR7ROCK2ROCK1CYP2C9
SCHEMBL19902610 0.85 CSF1R (0.55) SIK2SIK3
SCHEMBL19902632 0.79 KMT2A (0.51) ROCK2ROCK1PARP1
SCHEMBL19902390 0.77 CSF1R (0.54)
SCHEMBL17452935 0.76 CSF1R (0.49) ROCK2SIK2SIK3
SCHEMBL19902381 0.74 MAPK14 (0.42) ROCK2ROCK1MAPK14PARP1LRRK2
SCHEMBL19902573 0.74 MAPK8 (0.43) ROCK2ROCK1MAPK14PARP1LRRK2
SCHEMBL19902372 0.73 EPHX2 (0.49) ROCK2ROCK1EPHX2DRD2HTR2A
SCHEMBL20229915 0.72 ROCK2 (0.51) ROCK2ROCK1MAPK14
SCHEMBL9967230 0.72 AKT1 (0.59) LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 PPARG 2016/4885HTR7 2949/4885ROCK2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.